---
title: "Top Executive Sells Thousands of Celldex Shares!"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/269023651.md"
description: "Freddy A. Jimenez, SVP & GC of Celldex, sold 4,166 shares worth $121,188 on December 8, 2025. Celldex's Q3 2025 report shows progress in clinical trials but a net loss of $67 million. Despite strong cash reserves, Spark rates CLDX stock as Neutral due to weak financials and unattractive valuation metrics."
datetime: "2025-12-09T02:09:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269023651.md)
  - [en](https://longbridge.com/en/news/269023651.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269023651.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/269023651.md) | [繁體中文](https://longbridge.com/zh-HK/news/269023651.md)


# Top Executive Sells Thousands of Celldex Shares!

New insider activity at Celldex ( (CLDX) ) has taken place on December 8, 2025.

### TipRanks Cyber Monday Sale

-   Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

SVP & GC Freddy A. Jimenez recently sold 4,166 shares of Celldex stock, amounting to a total transaction value of $121,188.

**Recent Updates on CLDX stock**

Celldex Therapeutics recently released its Q3 2025 earnings report, highlighting significant progress in its clinical pipeline, particularly with positive Phase 2 results for barzolvolimab in treating chronic spontaneous urticaria and cold urticaria, as well as promising data for CDX-622. Despite reporting a net loss of $67 million due to increased R&D expenses, Celldex maintains a strong cash position expected to support operations through 2027. The company’s advancements in mast cell biology and promising trial results have been pivotal in justifying positive analyst ratings, with expectations for further data readouts in 2026 and potential commercialization of barzolvolimab.

**Spark’s Take on CLDX Stock**

According to Spark, TipRanks’ AI Analyst, CLDX is a Neutral.

Celldex’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis shows a lack of strong momentum, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall score.

To see Spark’s full report on CLDX stock, click here.

**More about Celldex**

**YTD Price Performance:** 14.19%

**Average Trading Volume:** 936,340

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1.96B

### 相关股票

- [Celldex Therap (CLDX.US)](https://longbridge.com/zh-CN/quote/CLDX.US.md)

## 相关资讯与研究

- [Celldex Therapeutics Prices $300 Mln Public Offering Of Shares At $29/shr; Stock Down](https://longbridge.com/zh-CN/news/281470537.md)
- [Celldex Announces Pricing of $300 Million Public Offering of Common Stock | CLDX Stock News](https://longbridge.com/zh-CN/news/281449180.md)
- [A Look At Celldex Therapeutics (CLDX) Valuation As Shares Show Renewed Momentum](https://longbridge.com/zh-CN/news/280937334.md)
- [Celldex Therapeutics Prices $29 Share Sale, Expects $282 Million Net From Underwritten Offering](https://longbridge.com/zh-CN/news/281522302.md)
- [Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results](https://longbridge.com/zh-CN/news/277110467.md)